Development and testing of in vitro companion assay for novel hypoxia-activated mitochondrial prodrugs****

新型缺氧激活线粒体前药的体外伴随测定的开发和测试****

• 批准号: 536832-2018
• 负责人: Karshafian, Raffi
• 金额: $ 1.82万
• 依托单位: Ryerson University
• 依托单位国家: 加拿大
• 项目类别: Engage Grants Program
• 财政年份: 2018
• 资助国家: 加拿大
• 起止时间: 2018-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=655150
• 关键词: Development; testing; vitro; companion; assay

Cyclica has developed a new technology, termed Differential Drug Discovery (DDD), to design single molecules capable of targeting multiple proteins simultaneously and retain drug like characteristics. The project will design tumour specific pro-drugs to target mitochondrial respiration. To achieve this Cyclica software developers must design constructs to predict chemical structures that will target various proteins in the mitochondria. Our team will develop a companion assay to test the novel chemical structures designed in the software and substantiate the computer aided predictions. We will perform optimization, benchmarking and assays required for Cyclica to proceed to the commercialization of the novel computational drug discovery application of their AI technology.**

Cyclica开发了一种称为差异药物发现（DDD）的新技术，用于设计能够同时靶向多种蛋白质并保留药物（如特征）的单分子。该项目将设计特定于肿瘤的促药，以靶向线粒体呼吸。为了实现此循环软件，必须设计构造，以预测将针对线粒体中各种蛋白质的化学结构。我们的团队将开发一种配套测定法，以测试软件中设计的新型化学结构并证实计算机的预测。我们将进行优化，基准测试和CYCLICA所需的测定，以继续进行新型计算药物发现其AI技术的应用。**